Treatment of non-small cell lung cancer in the era of targeted therapy

James Chung-Man Ho

Department of Medicine, The University of Hong Kong, Hong Kong, China.

DOI: 10.4236/alc.2012.11001                

Abstract

Lung cancer, mostly non-small cell carcinoma (NSCLC), is still a major global problem with devastating outcomes. The majority presents at late stages, in which the chance of cure is minimal. With the better understanding of lung cancer biology, there have been several novel targeted approaches against NSCLC. Anti-angiogenesis has been proven to be an important approach in combination with systemic chemotherapy treatment in NSCLC at the first-line setting. The prototypic monoclonal antibody against vascular endothelial growth factor (VEGF), be- vacizumab, is now approved for clinical use in combination with platinum-based chemotherapy in first-line treatment of advanced non-squamous NSCLC, associated with improved response and survival compared with chemotherapy alone. The most notable example of targeted therapy for lung cancer is epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI). There have been extensive evidences supporting the superiority of EGFR TKI (like gefitinib or erlotinib) over standard platinum-based doublet chemotherapy in first-line treatment of advanced NSCLC carrying EGFR activating mutations. Almost following the same path as EGFR TKI, a novel target (anaplastic lymphoma kinase, ALK) has been identified recently with a very promising targeted agent (crizotinib) that has already been approved for clinical use in NSCLC carrying ALK rearrangements. Over the past decade, there have been undoubtedly growing armamentaria in the treatment of NSCLC, focusing on personalized and targeted approach.

Keywords

Targeted Therapy; Non-Small Cell Lung Cancer; Bevacizumab; Erlotinib; Gefitinib; Crizotinib

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute, 82, 4-6. doi:10.1093/jnci/82.1.4
[2]	Folkman, J. (1971) Tumor angiogenesis: Therapeutic im- plications. New England Journal of Medicine, 285, 1182- 1186. doi:10.1056/NEJM197111182852108
[3]	Folkman, J. (1990) Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer and Metastasis Reviews, 9, 171-174. doi:10.1007/BF00046358
[4]	Takeda, A., Stoeltzing, O., Ahmad, S.A., Reinmuth, N., Liu, W., Parikh, A., Fan, F., Akagi, M. and Ellis, L.M. (2002) Role of angiogenesis in the development and growth of liver metastasis. Annals of Surgical Oncology, 9, 610-616. doi:10.1007/BF02574475
[5]	Hicklin, D.J. and Ellis, L.M. (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23, 1011- 1027. doi:10.1200/JCO.2005.06.081
[6]	Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., Langer, C.J., De- Vore, R.F. III, Gaudreault, J., Damico, L.A., Holmgren, E. and Kabbinavar, F. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology, 22, 2184-2191. doi:10.1200/JCO.2004.11.022
[7]	Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R. and Johnson, D.H. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Me- dicine, 355, 2542-2550. doi:10.1056/NEJMoa061884
[8]	Reck, M., Von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N. and Manegold, C. (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. Journal of Clinical Oncology, 27, 1227-1234. doi:10.1200/JCO.2007.14.5466
[9]	Dansin, E., Cinieri, S., Garrido, P., Griesinger, F., Isla, D., Koehler, M. and Kohlhaeufl, M.(2012) MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer, 76, 373-379. doi:10.1016/j.lungcan.2011.11.020
[10]	Giaccone, G., Herbst, R.S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R.B., Schiller, J.H., Von Pawel, J., Pluzanska, A., Gatzemeier, U., Grous, J., Ochs, J.S., Averbuch, S.D., Wolf, M.K., Rennie, P., Fandi, A. and Johnson, D.H. (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial—INTACT 1. Journal of Clinical Oncology, 22, 777-784. doi:10.1200/JCO.2004.08.001
[11]	Herbst, R.S., Giaccone, G., Schiller, J.H., Natale, R.B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J.A., Wolf, M.K., Krebs, A.D., Averbuch, S.D., Ochs, J.S., Grous, J., Fandi, A. and Johnson, D.H. (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial—INTACT 2. Journal of Clinical Oncology, 22, 785- 794. doi:10.1200/JCO.2004.07.215
[12]	Kris, M.G., Natale, R.B., Herbst, R.S., Lynch, T.J. Jr., Prager, D., Belani, C.P., Schiller, J.H., Kelly, K., Spiridonidis, H., Sandler, A., Albain, K.S., Cella, D., Wolf, M.K., Averbuch, S.D., Ochs, J.J. and Kay, A.C. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA, 290, 2149-2158. doi:10.1001/jama.290.16.2149
[13]	Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, T., Noda, K., Takata, I., Smit, E., Averbuch, S., Macleod, A., Feyereislova, A., Dong, R.P. and Baselga, J. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). Journal of Clinical Oncology, 21, 2237-2246. doi:10.1200/JCO.2003.10.038
[14]	Thatcher, N., Chang, A., Parikh, P., Rodrigues, P.J., Ciu- leanu, T., Von Pawel J., Thongprasert, S., Tan, E.H., Pem- berton, K., Archer, V. and Carroll, K. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Re- sults from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lan- cet, 366, 1527-1537. doi:10.1016/S0140-6736(05)67625-8
[15]	Perez-Soler, R. (2004) The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clini- cal Cancer Research, 10, 4238s-4240s. doi:10.1158/1078-0432.CCR-040017
[16]	Shepherd, F.A., Rodrigues, P.J., Ciuleanu, T., Tan, E.H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., Van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabarbara, P. and Seymour, L. (2005) Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353, 123-132. doi:10.1056/NEJMoa050753
[17]	Calvo, E. and Baselga, J. (2006) Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Clinical Oncology, 24, 2158- 2163. doi:10.1200/JCO.2006.06.5961
[18]	Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A. and Fukuoka, M. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361, 947-957. doi:10.1056/NEJMoa0810699
[19]	Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T. and North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New England Journal of Medicine, 362, 2380-2388. doi:10.1056/NEJMoa0909530
[20]	Zhou, C., Wu, Y.L., Chen, G., Feng, J., Liu, X.Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., Lu, S., Zhang, L., Hu, C., Hu, C., Luo, Y., Chen, L., Ye, M., Huang, J., Zhi, X., Zhang, Y., Xiu, Q., Ma, J., Zhang, L. and You, C. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncology, 12, 735-742. doi:10.1016/S1470-2045(11)70184-X
[21]	Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y. and Mano, H. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-566. doi:10.1038/nature05945
[22]	Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., J?nne, P.A., Costa, D.B., Varella-Garcia, M., Kim, W.H., Lynch, T.J., Fidias, P., Stubbs, H., Engelman, J.A., Sequist, L.V., Tan, W., Gandhi, L., Mino-Kenudson, M., Wei, G.C., Shreeve, S.M., Ratain, M.J., Settleman, J., Christensen, J.G., Haber, D.A., Wilner, K., Salgia, R., Shapiro, G.I., Clark, J.W. and Iafrate, A.J. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Jou